Last reviewed · How we verify
A Randomized, Controlled, Multicenter Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients
The purpose of this study is to determine whether monosialoganglioside are effective in the prevention of neurotoxicity induced by albumin-bound paclitaxel chemotherapy in lung cancer patients, and improve the quality of life of patients.
Details
| Lead sponsor | Peking University Cancer Hospital & Institute |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 106 |
| Start date | 2015-07 |
| Completion | 2018-12 |
Conditions
- Neurotoxicity
Interventions
- monosialoganglioside
Primary outcomes
- incidence of neurotoxicity — up to 4 weeks after the 2nd cycle albumin-bound paclitaxel chemotherapy
Countries
China